CU20170093A7 - Conjugados de ácidos grasos y apelina sintética con mayor vida media - Google Patents

Conjugados de ácidos grasos y apelina sintética con mayor vida media

Info

Publication number: CU20170093A7
Authority: CU; Cuba
Prior art keywords: conjugates; heart failure; fatty acid; synthetic; appeal
Prior art date: 2015-01-23

Application number

CUP2017000093A

Other languages

English (en)

Spanish (es)

Inventor

Aaron Kanter

Aimee Richardson Usera

Frederic Zecri

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-01-23

Filing date

2016-01-15

Publication date

2017-09-06

2016-01-15 Application filed by Novartis Ag filed Critical Novartis Ag

2017-09-06 Publication of CU20170093A7 publication Critical patent/CU20170093A7/xx

Links

235000014113 dietary fatty acids Nutrition 0.000 title abstract 3
229930195729 fatty acid Natural products 0.000 title abstract 3
239000000194 fatty acid Substances 0.000 title abstract 3
150000004665 fatty acids Chemical class 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
108091008803 APLNR Proteins 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
206010007556 Cardiac failure acute Diseases 0.000 abstract 1
206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
208000031229 Cardiomyopathies Diseases 0.000 abstract 1
102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 abstract 1
101710182628 DNA fragmentation factor subunit alpha Proteins 0.000 abstract 1
206010016807 Fluid retention Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
239000002202 Polyethylene glycol Substances 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
206010042496 Sunburn Diseases 0.000 abstract 1
208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
150000001408 amides Chemical class 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
206010003119 arrhythmia Diseases 0.000 abstract 1
230000006793 arrhythmia Effects 0.000 abstract 1
150000001735 carboxylic acids Chemical group 0.000 abstract 1
230000009787 cardiac fibrosis Effects 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
-1 cysteine amino acids Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
208000004104 gestational diabetes Diseases 0.000 abstract 1
208000023589 ischemic disease Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229920001223 polyethylene glycol Polymers 0.000 abstract 1
229920001184 polypeptide Polymers 0.000 abstract 1
201000011461 pre-eclampsia Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
208000002815 pulmonary hypertension Diseases 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
150000003573 thiols Chemical group 0.000 abstract 1
201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
230000009529 traumatic brain injury Effects 0.000 abstract 1
206010047302 ventricular tachycardia Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Diabetes (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Child & Adolescent Psychology (AREA)

CUP2017000093A 2015-01-23 2016-01-15 Conjugados de ácidos grasos y apelina sintética con mayor vida media CU20170093A7 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562107040P	2015-01-23	2015-01-23
PCT/IB2016/050206 WO2016116842A1 (fr)	2015-01-23	2016-01-15	Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée

Publications (1)

Publication Number	Publication Date
CU20170093A7 true CU20170093A7 (es)	2017-09-06

Family

ID=55229773

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CUP2017000093A CU20170093A7 (es)	2015-01-23	2016-01-15	Conjugados de ácidos grasos y apelina sintética con mayor vida media

Country Status (22)

Country	Link
US (1)	US9931372B2 (fr)
EP (1)	EP3247405B1 (fr)
JP (1)	JP2018507187A (fr)
KR (1)	KR20170103970A (fr)
CN (1)	CN107406490A (fr)
AR (1)	AR104479A1 (fr)
AU (1)	AU2016209968B2 (fr)
BR (1)	BR112017014194A2 (fr)
CA (1)	CA2972871A1 (fr)
CO (1)	CO2017007244A2 (fr)
CR (1)	CR20170338A (fr)
CU (1)	CU20170093A7 (fr)
EA (1)	EA201791668A1 (fr)
IL (1)	IL253105A0 (fr)
MA (1)	MA41580A (fr)
MX (1)	MX2017009534A (fr)
PE (1)	PE20171328A1 (fr)
PH (1)	PH12017501112A1 (fr)
SG (1)	SG11201704758XA (fr)
TW (1)	TW201632197A (fr)
UY (1)	UY36523A (fr)
WO (1)	WO2016116842A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
EP3684414A4 (fr) *	2017-09-19	2021-06-09	Immunwork Inc.	Constructions pharmaceutiques présentant une affinité de liaison améliorée avec l'albumine
WO2019229242A1 (fr)	2018-05-31	2019-12-05	Novo Nordisk A/S	Dérivés comprenant un analogue d'apeline et leurs utilisations
TW202304500A (zh) *	2021-04-21	2023-02-01	瑞士商諾華公司	升糖素樣肽化合物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2951135A1 (de)	1979-12-19	1981-06-25	Hoechst Ag, 6230 Frankfurt	Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4889861A (en)	1982-12-21	1989-12-26	Ciba-Geigy Corp.	Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en)	1984-06-20	1986-10-14	Ciba-Geigy Corporation	Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3347565A1 (de)	1983-12-30	1985-07-11	Thomae Gmbh Dr K	Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6354321A (ja)	1985-03-27	1988-03-08	Ajinomoto Co Inc	血糖降下剤
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5118666A (en)	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
DK0512042T3 (da)	1990-01-24	1998-05-11	Douglas I Buckley	GLP-1-analoger anvendelige ved diabetesbehandling
AU654331B2 (en)	1991-03-30	1994-11-03	Kissei Pharmaceutical Co. Ltd.	Succinic acid compounds
US5155100A (en)	1991-05-01	1992-10-13	Ciba-Geigy Corporation	Phosphono/biaryl substituted dipeptide derivatives
RU2086544C1 (ru)	1991-06-13	1997-08-10	Хоффманн-Ля Рош АГ	Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
KR100496720B1 (ko)	1991-06-21	2006-01-27	닥터.칼토매게엠베하	(s)(+)-2-에톡시-4[n-[1-(2-피페리디노페닐)-3-메틸-1-부틸]아미노카보닐메틸]-벤조산을함유하는당뇨병치료제
ATE149483T1 (de)	1991-07-30	1997-03-15	Ajinomoto Kk	Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
WO1993011782A1 (fr)	1991-12-19	1993-06-24	Southwest Foundation For Biomedical Research	Polypeptide inhibant la proteine de transfert aux esters de cholesteryl, anticorps contre le polypeptide synthetique et traitements prophylactiques et therapeutiques anti-atherosclerose
JPH09501655A (ja) *	1993-08-02	1997-02-18	コモンウェルスサイエンティフィックアンドインダストリアルリサーチオーガニゼーション	治療化合物−脂肪酸接合体
IL111785A0 (en)	1993-12-03	1995-01-24	Ferring Bv	Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TW313568B (fr)	1994-12-20	1997-08-21	Hoffmann La Roche
DE122010000020I1 (de)	1996-04-25	2010-07-08	Prosidion Ltd	Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
DE69838986T2 (de)	1997-12-24	2009-01-08	Takeda Pharmaceutical Co. Ltd.	Polypeptide, deren herstellung und verwendung
AU2605099A (en) *	1998-02-25	1999-09-15	Micrologix Biotech, Inc.	Indolicidin and cationic peptides conjugated with polymers
GT199900147A (es)	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en)	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6723752B2 (en)	1999-09-23	2004-04-20	Pharmacia Corporation	(R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
AU2001242749A1 (en)	2000-03-23	2001-10-03	Takeda Chemical Industries Ltd.	Peptide derivative
HUP0301335A3 (en)	2000-04-12	2006-02-28	Novartis Ag	Combination of organic compounds
DK2128246T3 (da)	2001-04-19	2014-05-12	Univ California	Fremgangsmåder og sammensætninger til fremstilling af ortogonale tRNA-aminoacyl-tRNA-syntetasepar.
ES2392073T3 (es)	2001-11-08	2012-12-04	Abbott Biotherapeutics Corp.	Formulación farmacéutica líquida estable de anticuerpos IGG
TW200407310A (en)	2002-06-07	2004-05-16	Glaxo Group Ltd	Compounds
ATE335744T1 (de)	2002-08-07	2006-09-15	Novartis Pharma Gmbh	Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
US7223866B2 (en)	2002-11-18	2007-05-29	Novartis Ag	Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases
WO2004078777A2 (fr) *	2003-03-04	2004-09-16	Biorexis Pharmaceutical Corporation	Proteines protegees contre la dipeptidylpeptidase
EA200601785A1 (ru)	2004-03-26	2007-02-27	Эли Лилли Энд Компани	Соединения и способы лечения дислипидемии
UA90269C2 (ru)	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
BRPI0511621A (pt)	2004-05-28	2008-01-02	Speedel Experimenta Ag	compostos orgánicos
US7612088B2 (en)	2004-05-28	2009-11-03	Speedel Experimenta Ag	Heterocyclic compounds and their use as aldosterone synthase inhibitors
TW200608978A (en)	2004-05-28	2006-03-16	Speedel Experimenta Ag	Organic compounds
AR049711A1 (es)	2004-07-09	2006-08-30	Speedel Experimenta Ag	Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
TW200716105A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Imidazole compounds
TW200716634A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
TW200716636A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
US8673848B2 (en) *	2012-01-27	2014-03-18	Novartis Ag	Synthetic apelin mimetics for the treatment of heart failure
AR056888A1 (es)	2005-12-09	2007-10-31	Speedel Experimenta Ag	Derivados de heterociclil imidazol
EA014232B1 (ru)	2005-12-20	2010-10-29	Бристол-Маерс Сквибб Компани	Стабильные белковые препараты
US20090156875A1 (en)	2006-04-04	2009-06-18	Takafumi Tomioka	Methane separation method, methane separation apparatus, and methane utilization system
TW200808813A (en)	2006-04-12	2008-02-16	Speedel Experimenta Ag	Imidazo compounds
TW200808812A (en)	2006-04-12	2008-02-16	Speedel Experimenta Ag	Imidazo compounds
AU2007247385B2 (en)	2006-05-10	2011-07-14	Novartis Ag	Bicyclic derivatives as CETP inhibitors
EP1886695A1 (fr)	2006-06-27	2008-02-13	Speedel Experimenta AG	Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
CA2657258A1 (fr)	2006-07-20	2008-01-24	Novartis Ag	Composes organiques
US20090264420A1 (en)	2006-08-25	2009-10-22	Gary Michael Ksander	Organic compounds
US8043829B2 (en) *	2006-10-25	2011-10-25	Amgen Inc.	DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
KR20090091817A (ko)	2006-12-18	2009-08-28	노파르티스 아게	알도스테론 신타제 억제제로서의 이미다졸
US8143278B2 (en)	2006-12-18	2012-03-27	Novartis Ag	Organic compounds
US20100041722A1 (en)	2006-12-18	2010-02-18	Qi-Ying Hu	Organic compounds
WO2008119744A1 (fr)	2007-03-29	2008-10-09	Novartis Ag	Spiro-composés hétérocycliques
TWI448284B (zh)	2007-04-24	2014-08-11	Theravance Inc	雙效抗高血壓劑
WO2009035543A1 (fr)	2007-09-07	2009-03-19	Theravance, Inc.	Agents antihypertensifs à double action
CA2704633C (fr)	2007-11-05	2015-10-20	Novartis Ag	Derives de 4-benzylamino-1-carboxyacyl-piperidine en tant qu'inhibiteurs de cetp utiles pour le traitement de maladies telles que l'hyperlipidemie ou l'arteriosclerose
PT2229356E (pt)	2007-12-03	2012-01-20	Novartis Ag	Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
WO2009134741A1 (fr)	2008-04-29	2009-11-05	Theravance, Inc.	Agents antihypertenseurs à double action
AR072297A1 (es)	2008-06-27	2010-08-18	Novartis Ag	Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
KR20110039348A (ko) *	2008-08-06	2011-04-15	노보 노르디스크 헬스 케어 악티엔게젤샤프트	연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
KR101316159B1 (ko)	2008-10-24	2013-10-15	아이알엠 엘엘씨	생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형
WO2010053545A2 (fr) *	2008-11-04	2010-05-14	Anchor Therapeutics, Inc.	Composés de récepteur apj
KR101338555B1 (ko)	2009-05-15	2013-12-09	노파르티스 아게	알도스테론 신타제 억제제로서의 아릴 피리딘
CA2763572C (fr)	2009-05-28	2017-10-17	Novartis Ag	Derives aminopropioniques substitues comme inhibiteurs de neprilysine
MA33364B1 (fr)	2009-05-28	2012-06-01	Novartis Ag	Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CN106139158B (zh) *	2010-01-22	2024-06-21	诺沃—诺迪斯克保健股份有限公司	体内功效延长的生长激素
TW201138808A (en)	2010-05-03	2011-11-16	Bristol Myers Squibb Co	Serum albumin binding molecules
CN103179976A (zh)	2010-05-13	2013-06-26	印第安纳大学研究及科技有限公司	呈现g蛋白偶联受体活性的胰高血糖素超家族肽
SI3045183T1 (sl)	2011-03-11	2018-11-30	Genzyme Corporation	Pegiliran Apelin in njegove uporabe
CA2860740A1 (fr) *	2012-01-09	2013-07-18	Anchor Therapeutics, Inc.	Composes de recepteurs apj
ES2875957T3 (es)	2012-12-20	2021-11-11	Amgen Inc	Agonistas del receptor APJ y usos de los mismos
BR112015020587A2 (pt)	2013-03-14	2017-10-10	Regeneron Pharma	proteínas de fusão de apelina e suas utilizações
AU2014293387B2 (en) *	2013-07-25	2017-04-20	Novartis Ag	Bioconjugates of synthetic apelin polypeptides
TW201536814A (zh)	2013-07-25	2015-10-01	Novartis Ag	用於治療心臟衰竭之合成環狀多肽
MX370689B (es)	2014-06-10	2019-12-19	Amgen Inc	Polipeptidos apelina.
US10588980B2 (en) *	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
US20170355734A1 (en)	2014-12-23	2017-12-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor

2016
- 2016-01-15 MA MA041580A patent/MA41580A/fr unknown
- 2016-01-15 KR KR1020177022999A patent/KR20170103970A/ko not_active Withdrawn
- 2016-01-15 EP EP16701560.1A patent/EP3247405B1/fr active Active
- 2016-01-15 JP JP2017538728A patent/JP2018507187A/ja active Pending
- 2016-01-15 WO PCT/IB2016/050206 patent/WO2016116842A1/fr not_active Ceased
- 2016-01-15 CA CA2972871A patent/CA2972871A1/fr not_active Abandoned
- 2016-01-15 SG SG11201704758XA patent/SG11201704758XA/en unknown
- 2016-01-15 AU AU2016209968A patent/AU2016209968B2/en not_active Ceased
- 2016-01-15 CN CN201680006640.0A patent/CN107406490A/zh active Pending
- 2016-01-15 CU CUP2017000093A patent/CU20170093A7/xx unknown
- 2016-01-15 PE PE2017001257A patent/PE20171328A1/es not_active Application Discontinuation
- 2016-01-15 BR BR112017014194A patent/BR112017014194A2/pt not_active IP Right Cessation
- 2016-01-15 MX MX2017009534A patent/MX2017009534A/es unknown
- 2016-01-15 US US14/996,418 patent/US9931372B2/en active Active
- 2016-01-15 EA EA201791668A patent/EA201791668A1/ru unknown
- 2016-01-15 CR CR20170338A patent/CR20170338A/es unknown
- 2016-01-20 UY UY0001036523A patent/UY36523A/es not_active Application Discontinuation
- 2016-01-22 TW TW105102112A patent/TW201632197A/zh unknown
- 2016-01-22 AR ARP160100180A patent/AR104479A1/es unknown
2017
- 2017-06-15 PH PH12017501112A patent/PH12017501112A1/en unknown
- 2017-06-22 IL IL253105A patent/IL253105A0/en unknown
- 2017-07-19 CO CONC2017/0007244A patent/CO2017007244A2/es unknown

Also Published As

Publication number	Publication date
BR112017014194A2 (pt)	2018-01-09
EP3247405A1 (fr)	2017-11-29
US9931372B2 (en)	2018-04-03
JP2018507187A (ja)	2018-03-15
CR20170338A (es)	2017-09-12
PE20171328A1 (es)	2017-09-12
US20160213743A1 (en)	2016-07-28
MA41580A (fr)	2017-11-29
EP3247405B1 (fr)	2019-07-17
UY36523A (es)	2016-08-31
AU2016209968B2 (en)	2018-11-29
AU2016209968A1 (en)	2017-07-20
EA201791668A1 (ru)	2017-11-30
CN107406490A (zh)	2017-11-28
WO2016116842A1 (fr)	2016-07-28
SG11201704758XA (en)	2017-08-30
PH12017501112A1 (en)	2017-11-27
CO2017007244A2 (es)	2017-10-10
KR20170103970A (ko)	2017-09-13
IL253105A0 (en)	2017-08-31
WO2016116842A9 (fr)	2016-12-08
MX2017009534A (es)	2018-04-10
AR104479A1 (es)	2017-07-26
CA2972871A1 (fr)	2016-07-28
TW201632197A (zh)	2016-09-16

Publication	Publication Date	Title
CU24266B1 (es)	2017-07-04	Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
EA201690282A1 (ru)	2016-09-30	Биоконъюгаты синтетических апелиновых полипептидов
CU20160013A7 (es)	2016-08-31	Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca
UY35144A (es)	2014-06-30	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CU20170093A7 (es)	2017-09-06	Conjugados de ácidos grasos y apelina sintética con mayor vida media
CY1123307T1 (el)	2021-12-31	Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
PH12015500375A1 (en)	2015-04-20	Nep inhibitors for treating diseases characterized by atrial enlargemenet or remodeling
JP2018048157A5 (fr)	2018-05-31
PE20241305A1 (es)	2024-06-24	Analogos de amilina
ES2765281T3 (es)	2020-06-08	Coadministración de un agente unido a un péptido de interiorización con un agente antiinflamatorio
JP2015506370A5 (fr)	2016-03-17
JP2016527249A5 (fr)	2017-09-07
HRP20110086T1 (hr)	2011-03-31	Dha esteri i njihova upotreba u tretmanu i prevenciji kardiovaskularnih bolesti
EA201070315A1 (ru)	2010-08-30	Жидкая лекарственная форма конъюгата
JP2018507187A5 (fr)	2019-02-21
WO2016084935A1 (fr)	2016-06-02	Promoteur de production du collagène de type iii
JP7107968B2 (ja)	2022-07-27	血管新生を促進する薬剤ならびにその方法および使用
HRP20150265T1 (hr)	2015-04-10	Pantenil-dokosaheksanoat i njegova upotreba za lijeäśenje i sprjeäśavanje kardiovaskularnih bolesti
TN2016000029A1 (en)	2017-07-05	Bioconjugates of synthetic apelin polypeptides
MA38864A1 (fr)	2017-11-30	Polypeptides cycliques pour le traitement de l'insuffisance cardiaque